Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

K Mross, S Steinbild, F Baas, M Reil, P Buss, S Mersmann, D Voliotis, B Schwartz, E Brendel

Journal: International journal of clinical pharmacology and therapeutics 2004;41(12):618-9

PMID: 14692719

Abstract

Address: Tumor Biology Center, Albert-Ludwigs-University Freiburg, Germany. [email protected]

Other Literature Sources:

Miscellaneous:

Research Materials:

MeSH Terms: Administration, Oral, Antineoplastic Agents, Phytogenic, Benzenesulfonates, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Interactions, Humans, Irinotecan, Neoplasms, Niacinamide, Phenylurea Compounds, Proto-Oncogene Proteins c-raf, Pyridines, Sorafenib